132 related articles for article (PubMed ID: 37950162)
1. Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.
Najafi S; Ansari M; Omidi Z; Olfatbakhsh A; Moghadam S; Hashemi EO; Najafi N; Haghighat S
BMC Cancer; 2023 Nov; 23(1):1093. PubMed ID: 37950162
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial.
Fazeli F; Nowroozi MR; Ayati M; Latifi S; Taheri Mahmoodi M; Norouzi Javidan A; Jamshidian H; Arbab A
Nephrourol Mon; 2015 May; 7(3):e27107. PubMed ID: 26290848
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide.
Karimi-Zarchi M; Forat-Yazdi M; Vafaeenasab MR; Nakhaie-Moghadam M; Miratashi-Yazdi A; Teimoori S; Dehghani-Tafti A
Eur J Gynaecol Oncol; 2014; 35(1):59-61. PubMed ID: 24654464
[TBL] [Abstract][Full Text] [Related]
4. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
Wang L; Zhang WX; Jiang H
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
[TBL] [Abstract][Full Text] [Related]
5. Is Menstruation or the Serum Hormone Level a Useful Predictor for Live Birth after Gonadotropin-Releasing Hormone Agonist during Chemotherapy in Young Breast Cancer Patients.
Lee DY; Choi D
Gynecol Obstet Invest; 2017; 82(6):601-606. PubMed ID: 28006769
[TBL] [Abstract][Full Text] [Related]
6. Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles.
Tehraninejad ESh; Nekoo EA; Ezabadi Z; Rashidi BH; Amirchaghmaghi E; Matroud EP
Arch Med Sci; 2010 Dec; 6(6):945-9. PubMed ID: 22427771
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
8. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.
Kurebayashi J; Toyama T; Sumino S; Miyajima E; Fujimoto T
Breast Cancer; 2017 Jan; 24(1):161-170. PubMed ID: 27017207
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
12. Follicle-stimulating hormone is the main determinant of follicular recruitment and development in ovulation induction with human menopausal gonadotropin.
Vermesh M; Kletzky OA
Am J Obstet Gynecol; 1987 Dec; 157(6):1397-402. PubMed ID: 3122575
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
[TBL] [Abstract][Full Text] [Related]
14. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression.
Melli MS; Farzadi L; Madarek EO
Saudi Med J; 2007 Mar; 28(3):445-50. PubMed ID: 17334477
[TBL] [Abstract][Full Text] [Related]
16. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure.
Cohen I; Tepper R; Figer A; Flex D; Shapira J; Beyth Y
Breast Cancer Res Treat; 1999 May; 55(2):119-25. PubMed ID: 10481939
[TBL] [Abstract][Full Text] [Related]
17. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
18. [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation].
Liu CQ; Qin ZX; Jiang FF; Hong T; Wang F
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Nov; 34(11):1288-91. PubMed ID: 25566615
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
20. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
